Oncology corporate
1 – 29 of 29
- show: 50
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Tattoos as a risk factor for malignant lymphoma: a population-based case–control study
(
- Contribution to journal › Article
-
Mark
Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE) : a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network
(
- Contribution to journal › Article
-
Mark
MRD-driven treatment with venetoclax-R2 in mantle cell lymphoma : the Nordic Lymphoma Group MCL7 VALERIA trial
(
- Contribution to journal › Article
-
Mark
Outcomes for patients with secondary CNS involvement in relapsed/refractory diffuse large B-cell lymphoma and estimation of eligibility for CAR T-cell therapy
(
- Contribution to journal › Letter
-
Mark
ESMO Clinical Practice Guideline interim update on the use of targeted therapy in acute lymphoblastic leukaemia
(
- Contribution to journal › Article
-
Mark
Primary central nervous system lymphomas : EHA–ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up☆
(
- Contribution to journal › Article
-
Mark
Primary central nervous system lymphomas : EHA–ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
(
- Contribution to journal › Article
-
Mark
The National Swedish Lymphoma Register – a systematic validation of data quality
(
- Contribution to journal › Article
- 2023
-
Mark
Late effects in patients with mantle cell lymphoma treated with or without autologous stem cell transplantation
(
- Contribution to journal › Article
-
Mark
Real-world experience among patients with relapsed/refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor failure in Europe : The SCHOLAR-2 retrospective chart review study
(
- Contribution to journal › Article
-
Mark
Overexpression of the key metabolic protein CPT1A defines mantle cell lymphoma patients with poor response to standard high dose chemotherapy independent of MIPI and complement established high-risk factors
(
- Contribution to journal › Article
-
Mark
Exploring new prognostic biomarkers in Mantle Cell Lymphoma : a comparison of the circSCORE and the MCL35 score
(
- Contribution to journal › Article
-
Mark
HPV self-sampling versus healthcare provider collection on the effect of cervical cancer screening uptake and costs in LMIC : a systematic review and meta-analysis
(
- Contribution to journal › Article
-
Mark
Secondary malignancies among mantle cell lymphoma patients
(
- Contribution to journal › Article
-
Mark
Nationwide Assessment of Patient Trajectories in Mantle Cell Lymphoma : The Swedish MCL complete Project
(
- Contribution to journal › Article
-
Mark
Soluble CD163 predicts outcome in both chemoimmunotherapy and targeted therapy–treated mantle cell lymphoma
(
- Contribution to journal › Article
- 2022
-
Mark
Outcomes of relapsed/refractory diffuse large B-cell lymphoma and influence of chimaeric antigen receptor T trial eligibility criteria in second line—A population-based study of 736 patients
(
- Contribution to journal › Article
-
Mark
Clinical and biological impact of SAMHD1 expression in mantle cell lymphoma
(
- Contribution to journal › Article
-
Mark
Idelalisib in relapsed/refractory diffuse large B-cell lymphoma : results from a Nordic Lymphoma Group phase II trial
(
- Contribution to journal › Letter
-
Mark
High-risk subtypes of chronic lymphocytic leukemia are detectable as early as 16 years prior to diagnosis
(
- Contribution to journal › Article
-
Mark
Evalutation of two commercial deep learning OAR segmentation models for prostate cancer treatment
2022) ESTRO 2022(
- Contribution to conference › Abstract
-
Mark
Tackling Mantle Cell Lymphoma in Europe
(
- Contribution to journal › Article
-
Mark
Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma
(
- Contribution to journal › Article
- 2021
-
Mark
Detecting deviations from the efficacy and safety results of single-arm trials using real-world data : The case of a CAR-T cell therapy in B-cell lymphoma
2021) In Pharmacoepidemiology and Drug Safety(
- Contribution to journal › Article
-
Mark
Clinical characteristics and histopathological patterns of hodgkin lymphoma and treatment outcomes at a tertiary cancer center in ethiopia
(
- Contribution to journal › Article
-
Mark
Targeted genomic investigations in a population-based cohort of mantle cell lymphoma reveal novel clinically relevant targets
(
- Contribution to journal › Article
-
Mark
American Society of Transplantation and Cellular Therapy, Center of International Blood and Marrow Transplant Research, and European Society for Blood and Marrow Transplantation Clinical Practice Recommendations for Transplantation and Cellular Therapies in Mantle Cell Lymphoma
(
- Contribution to journal › Article
- 2020
-
Mark
Subclonal patterns in follow-up of acute myeloid leukemia combining whole exome sequencing and ultrasensitive IBSAFE digital droplet analysis
(
- Contribution to journal › Article
- 2019
-
Mark
Is there a role for immunomodulatory drugs in the treatment of mantle cell lymphoma?
(
- Contribution to journal › Article